Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Conquest Research

Neither a doctor nor a teaching hospital

Research payments

$9,004,311

300 payments

Through program year 2025, Conquest Research is reported as receiving $9,004,311 in research payments, across 300 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,966,096 127
2024 Research $2,249,498 24
2023 Research $1,721,645 40
2022 Research $766,617 47
2021 Research $1,316,178 35
2020 Research $976,027 26
2019 Research $8,250 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,682,098 19 payments
  2. Amgen Inc. $1,845,397 1 payment
  3. AbbVie, Inc. $1,348,414 70 payments
  4. Vertex Pharmaceuticals Incorporated $977,446 4 payments
  5. Pfizer Inc. $711,460 56 payments
  6. Mesoblast, Inc. $669,345 12 payments
  7. Boehringer Ingelheim International GmbH $267,761 101 payments
  8. Biogen, Inc. $216,002 3 payments
  9. Flexion Therapeutics, Inc. $139,452 2 payments
  10. Novo Nordisk AS $85,344 29 payments
Studies the money was for Research payments · program years 2019–2025
  1. P4 Uncontrolled Gout FORWARD II $1,845,397 1 payment
  2. An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $1,153,255 3 payments
  3. M19-944 $772,455 23 payments
  4. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $748,034 2 payments
  5. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $711,403 55 payments
  6. Msb-Dr004 $669,345 12 payments
  7. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $557,826 3 payments
  8. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period $412,275 20 payments
  9. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $290,885 3 payments
  10. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $236,063 74 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record